© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#EASL 2012
Click Here for More Conferences
Click Here for EASL.eu
An Introduction to Hepatitis

Interferon-Free BMS Combo Yields 77% Cure Rate in Geno 1 Hep C

A 24-week, interferon-free regimen pairing two drugs from Bristol-Myers Squibb--60 milligrams (mg) of daclatasvir, a once-daily NS5a...

PILOT Study: Three-Month Interferon-Free Regimen Cures 9 of 11 Geno 1, IL-28B CC Hep C Patients

A 12-week, interferon-free combination of two experimental, once-daily drugs cured nine of 11 (82 percent) first-time treatment takers

COPILOT Study: Second Three-Month Inteferon-Free Abbott Regimen Versus Geno 1 Hep C

A 12-week regimen of ribavirin plus two experimental drugs kept HCV levels undetectable for 12 weeks after completing treatment in over 90%

MUST read

Hepatitis C: The Basics
Hepatitis B: The Basics
Hepatitis A: The Basics

Efficacy of 12-Week GS-7977/Ribavirin Combo for Hep C Geno 1 Varies by IL-28B Status

Early follow-up data continues to show promise as a cornerstone of interferon-free treatment

Interferon-Free Gilead and BMS Combo Shows High Cure Rate Potential

All-oral treatment kept undetectable for four weeks after treatment in 100% of people genotype 1 infection and 91% of people with 2 or 3

Novel Lambda Peg-Interferon Has Safety Edge Over Approved Peg-Interferon

A novel version of interferon, pegylated interferon lambda-1a (peg-IFN-lambda), combined with ribavirin cured up to three-quarters of...

Hot topics

Forums: Support and discussion
Blogs: The community speaks

90% Geno 1 Patients Nearing Cure in 7977/Interferon Study

Ninety percent of people with genotype 1 hepatitis C virus (HCV) starting therapy for the first time show a clear sign of being cured

TMC435 Boosts Cure Rates in Previously Treated Geno 1 HCV Patients

Up to 80 percent of people with genotype 1 hepatitis C virus (HCV) who didn’t respond successfully to earlier therapy were cured

Victrelis Shows Effectiveness for Prior Treatment Null Responders

Additional data from a Merck-sponsored clinical trial help clarify the efficacy of Victrelis combined with interferon and ribavirin
Advertisement
Science News
Newsfeed
Features
Ask Hep